Roth Affirms AcelRx (ACRX) at 'Buy' Following Zalviso Update
Tweet Send to a Friend
Roth Capital affirms AcelRx Pharmaceuticals (Nasdaq: ACRX) with a Buy rating and $10.50 price target after the company provided a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
